SCHEMBL640427

SCHEMBL640427

CCOC(=O)C(=O)c1ccc(SC)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.52
MAPT P10636 5/20 0.52
KDM4E B2RXH2 3/20 0.52
LMNA P02545 4/20 0.49
NPSR1 Q6W5P4 3/20 0.49
TSHR P16473 3/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
PLK1 P53350 1/20 0.46
MAPK1 P28482 1/20 0.46
POLB P06746 1/20 0.44
TAS1R3 Q7RTX0 1/20 0.44
TAS1R1 Q7RTX1 1/20 0.44
HRH2 P25021 1/20 0.42
HRH1 P35367 1/20 0.42
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
ESR1 P03372 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21636243 0.87 ALDH1A1 (0.49) ALDH1A1MAPTKDM4ELMNANPSR1
SCHEMBL1023962 0.84 RAB9A (0.57) ALDH1A1MAPTKDM4ELMNAMEN1
SCHEMBL147669 0.81 MEN1 (0.67) ALDH1A1MAPTLMNANPSR1TSHR
SCHEMBL12574524 0.81 NPC1 (0.44) ALDH1A1MAPTKDM4ELMNATSHR
SCHEMBL1866387 0.81 ALDH1A1 (0.44) ALDH1A1MAPTKDM4ELMNANPSR1
SCHEMBL11495774 0.81 ALDH1A1 (0.55) ALDH1A1MAPTLMNATSHRMEN1
SCHEMBL167161 0.81 CES2 (0.60) ALDH1A1MAPTLMNAKMT2ASMN1; SMN2
SCHEMBL21636244 0.81 MAPT (0.53) ALDH1A1MAPTKDM4ELMNATSHR
SCHEMBL22213368 0.80 ALDH1A1 (0.43) ALDH1A1MAPTKDM4ELMNANPSR1
SCHEMBL1695099 0.80 HAO1 (0.59) ALDH1A1MAPTKDM4ELMNANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4038164-A PHOTOPOLYMERIZABLE ARYL AND HETEROCYCLIC GLYOXYLATE COMPOSITIONS AND PROCESS STAUFFER CHEMICAL COMPANY (US) 1977-07-26 US claimed
US-11535590-B2 Sulfonium salt photoinitiator, preparation method therefor, photocurable composition comprising sulfonium salt photoinitiator, and use thereof CHANGZHOU TRONLY NEW ELECTRONIC MATERIALS CO., LTD. (CN) 2022-12-27 US disclosed
WO-2020015966-A1 PHOTO-CURABLE RESIN COMPOSITION FOR 3D PRINTING CLARIANT INTERNATIONAL LTD (CH) 2020-01-23 WO disclosed
WO-2020015964-A1 PHOTO-CURABLE RESIN COMPOSITION FOR 3D PRINTING CLARIANT INTERNATIONAL LTD (CH) 2020-01-23 WO disclosed
US-9452977-B2 Cyclopentylacrylamide derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2016-09-27 US disclosed
EP-2275414-B1 CYCLOPENTYLACRYLAMIDE DERIVATIVE KYORIN SEIYAKU KK (JP) 2015-06-10 EP disclosed
US-20150105581-A1 CYCLOPENTYLACRYLAMIDE DERIVATIVE TEIJIN LIMITED (JP) 2015-04-16 US disclosed
US-8946440-B2 Cyclopentylacrylamide derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2015-02-03 US disclosed
US-8414982-B2 Process for the production of strongly adherent coatings BASF SE (DE) 2013-04-09 US disclosed
US-8119626-B2 Oxime derivative and preparations thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-02-21 US disclosed
EP-1242397-B1 TRANS OLEFINIC GLUCOKINASE ACTIVATORS HOFFMANN LA ROCHE (CH) 2005-09-28 EP disclosed
EP-1487797-A1 HETERO-BRIDGE SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS Merck Frosst Canada & Co. (CA) 2004-12-22 EP disclosed
WO-2004063179-A1 SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS ELI LILLY AND COMPANY (US) 2004-07-29 WO disclosed
WO-2003078397-A1 HETERO-BRIDGE SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS MERCK FROSST CANADA & CO. (CA) 2003-09-25 WO disclosed
US-6596445-B1 Initiators for photopolymerization of radically polymerizable compounds CIBA SPECIALTY CHEMICALS CORPORATION 2003-07-22 US disclosed
WO-2003002118-A1 SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS MERCK FROSST CANADA & CO. (CA) 2003-01-09 WO disclosed
EP-1242397-A1 TRANS OLEFINIC GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2002-09-25 EP disclosed
US-6353111-B1 WHICH INCREASE INSULIN SECRETION IN THE TREATMENT OF TYPE II DIABETES; 2,3-DI-SUBSTITUTED TRANS OLEFINIC N-HETEROAROMATIC OR URIDO PROPIONAMIDES: THE SUBSTITUTION AT THE 2-POSITION BEING A SUBSTITUTED PHENYL GROUP AND AT THE 3-POSITION A HOFFMANN-LA ROCHE INC. 2002-03-05 US disclosed
WO-2001044216-A1 TRANS OLEFINIC GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2001-06-21 WO disclosed
US-4229274-A PHOTOINITIATOR, PHOTOSENSITIZER, QUENCHER, AND COMPOUNDS CONTAINING ACRYLYLOXY GROUPS PPG INDUSTRIES, INC. (US) 1980-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150105581-A1 CYCLOPENTYLACRYLAMIDE DERIVATIVE GPR119, SLC5A1, SLC5A2 ALDH1A1 606/4885MAPT 4834/4885KDM4E 2516/4885
US-11535590-B2 Sulfonium salt photoinitiator, preparation method therefor, photocurable composition comprising sulfonium salt photoinitiator, and use thereof OR51E2, SULT1A1, TRPA1 ALDH1A1 275/4885MAPT 1340/4885KDM4E 3921/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.